Grau-Pujol, 269 patient HCQ prophylaxis RCT: 11% fewer cases [p=1] https://c19p.org/graupujol
copied to clipboard
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial
et al., Trials, doi:10.1186/s13063-021-05758-9
Small PrEP RCT showing that PrEP with HCQ is safe at the dosage used. There were no deaths, hospitalizations, or serious adverse events.The paper states: "Among all trial participants at the end of the first month (n=253), only one participant from the placebo arm (1/116, 0.8%), tested positive for SARS-CoV-2 PCR and for a SARS-CoV-2 serology test".The abstract states: "only one participant in each group was diagnosed with COVID-19".
|
risk of case, 10.6% lower, RR 0.89, p = 1.00, treatment 1 of 142 (0.7%), control 1 of 127 (0.8%), NNT 1202.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Grau-Pujol et al., 9/21/2020, Randomized Controlled Trial, Spain, Europe, peer-reviewed, 22 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.